ArticleAlzheimer disease and associated disorders
Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.
Article in Alzheimer disease and associated disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 15 citations in OpenAlex.
- Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.Journal of Alzheimer's disease : JAD · 2020Article
- Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.Alzheimer's research & therapy · 2017Article
- Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease.Human brain mapping · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesOff-label medication use for treating cognitive impairments and neuropsychiatric symptoms occurs in frontotemporal dementia (FTD) and Alzheimer disease (AD). We compared the use of cognitive and psychiatric medications in FTD and AD and evaluated the relationship between neuropsychiatric symptoms and medication use.
methodsCognitive and psychiatric medication use, demographic variables, and Neuropsychiatric Inventory (NPI) subscale symptoms were obtained from the National Alzheimer's Coordinating Center Uniform Data Set (n=3958, 8.1% FTD). Bivariate statistics and logistic regressions were calculated to evaluate which demographic or NPI subscale symptoms predicted medication use.
resultsAlthough cognitive medication was used more commonly in AD (78%), it was also commonly used off-label in FTD (56%). Psychiatric medications were in greater use in FTD than in AD (68% vs. 45%, respectively, P<0.001). In FTD, cognitive medication use was associated with elevated NPI elation scores and psychiatric medication use was associated with history of prior psychiatric disease. In AD, demographic variables (white, longer disease duration, higher education, more severe disease, or being male) were most predictive of cognitive medication use, whereas having psychiatric disease, being white, having longer disease duration, being younger, greater disease severity, and being disinhibited or anxious were associated with psychiatric medication use. Off-label antipsychotics were used by 4.7% of patients with AD and 10% of patients with FTD.
conclusionsOur results revealed significant off-label medication use in both FTD and AD. A notable finding from this study was the lack of consistent relationships between medication use and neuropsychiatric symptoms across the 2 illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.